Reducing Hemostatic Activation during Cardiopulmonary Bypass: A Combined Approach

Anesthesia and Analgesia

Volumn 98, Issue 5, 2004, Pages 1208-1216

  Eisses, Michael J ^a,c   Seidel, Kristy ^b   Aldea, Gabriel S ^a   Chandler, Wayne L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; BIOLOGICAL MARKER; D DIMER; FIBRIN; FIBRINOPEPTIDE A; HEPARIN; ISOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INTERMETHOD COMPARISON; MALE; OPEN HEART SURGERY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SURGICAL TECHNIQUE; TIME;

EID: 1942533022     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ANE.0000108489.88613.2C     Document Type: Article

References (39)

1. Aldea GS, Doursounian M, O'Gara P, et al. Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: a prospective, randomized study. Ann Thorac Surg 1996;62:410-7; discussion 7-8.
2. Aldea GS, Lilly K, Gaudiani JM, et al. Heparin-bonded circuits improve clinical outcomes in emergency coronary artery bypass grafting. J Card Surg 1997;12:389-97.
3. Gorman R, Ziats N, Rao AK, et al. Cardiopulmonary bypass, myocardial management, and support techniques: surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg 1996; 111:1-12.
4. Grossi EA, Kallenbach K, Chau S, et al. Impact of heparin bonding on pediatric cardiopulmonary bypass: a prospective randomized study. Ann Thorac Surg 2000;70:191-6.
5. Spiess B, Vocelka C, Cochran R, et al. Heparin coated bypass circuits (Carmeda) suppress the release of tissue plasminogen activator during normothermic coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 1998;12:299-304.
6. Dietrich W. Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin? J Cardiovasc Pharmacol 1996;27:S50-7.
7. Eberle B, Mayer E, Hafner G, et al. High-dose epsilon-aminocaproic acid versus aprotinin: antifibrinolytic efficacy in first-time coronary operations. Ann Thorac Surg 1998;65:667-73.
8. Slaughter TF, Faghih F, Greenberg CS, et al. The effects of epsilon-aminocaproic acid on fibrinolysis and thrombin generation during cardiac surgery. Anesth Analg 1997;85:1221-6.
9. Aldea GS, Soltow LO, Chandler WL, et al. Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits. J Thorac Cardiovasc Surg 2002;123:742-55.
10. Spanier T, Tector K, Schwartz G, et al. Endotoxin in pooled pericardial blood contributes to the systemic inflammatory response during cardiac surgery. Perfusion 2000;15:427-31.
11. Aldea GS, O'Gara P, Shapira OM, et al. Effect of anticoagulation protocol on outcome in patients undergoing CABG with heparin-bonded cardiopulmonary bypass circuits. Ann Thorac Surg 1998;65:425-33.
12. Chandler WL, Fitch J, Wall M, et al. Individual variations in the fibrinolytic response during and after cardiopulmonary bypass. Thromb Haemost 1995;74:1293-7.
13. Boisclair MD, Lane DA, Philippou H, et al. Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin F1+2. Thromb Haemost 1993;70:253-8.
14. Grossmann R, Babin-Ebell J, Misoph M, et al. Changes in coagulation and fibrinolytic parameters caused by extracorporeal circulation. Heart Vessels 1996;11:310-7.
15. Dietrich W, Spannagl M, Jochum M, et al. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology 1990;73:1119-26.
16. Valen G, Eriksson E, Risberg B, Vaage J. Fibrinolysis during cardiac surgery: release of tissue plasminogen activator in arterial and coronary sinus blood. Eur J Cardiothorac Surg 1994;8: 324-30.
17. Shirota K, Watanabe T, Yashushi T, et al. Maintenance of blood heparin concentration rather than activated clotting time better preserves the coagulation system in hypothermic cardiopulmonary bypass. Artif Organs 2000;24:49-56.
18. Petaja J, Peltola K, Sairanen H, et al. Fibrinolysis, antithrombin III, and protein C in neonates during cardiac operations. J Thorac Cardiovasc Surg 1996;112:665-71.
19. Daily PO, Lamphere JA, Dembitsky WP, et al. Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting: a randomized, prospective, double-blind study. J Thorac Cardiovasc Surg 1994;108:99-106; discussion 106-8.
20. Vander Salm TJ, Kaur S, Lancey RA, et al. Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid. J Thorac Cardiovasc Surg 1996;112: 1098-107.
21. Chandler WL, Jascur ML, Hemderson PJ. Measurement of different forms of tPA in plasma. Clin Chem 2000;46:38-46.
22. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
23. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988;44: 1049-60.
24. Bannan S, Danby A, Cowan D, et al. Cell activation and thrombin generation in heparin bonded cardiopulmonary bypass circuits using a novel in vitro model. Eur J Cardiothorac Surg 1997;12:268-75.
25. O'Gara PJ, Treanor PR, Lilly KJ, et al. Technique for routine use of heparin bonded circuits with a reduced anticoagulation protocol. J Extra Corpor Technol 2000;32:207-13.
26. Ovrum E, Brosstad F, Holen EA, et al. Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass. Circulation 1995;92:2579-84.
27. Inui K, Shimazaki Y, Watanabe T, et al. Effects of Duraflo II heparin-coated cardiopulmonary bypass circuits on the coagulation system, endothelial damage, and cytokine release in patients with cardiac operation employing aprotinin and steroids. Artif Organs 1999;23:1107-12.
28. Martens S, Matheis G, Wimmer-Greinecker G, et al. Heparin coating of the extracorporeal circuit combined with leukocyte filtration reduces coagulation activity, blood loss and blood product substitution. Int J Artif Organs 2001;24:484-8.
29. Nakajima T, Osawa S, Ogawa M, et al. Clinical study of platelet function and coagulation/fibrinolysis with Duraflo II heparin coated cardiopulmonary bypass equipment. ASAIO J 1996;42: 301-5.
30. Philippou H, Adami A, Davidson SJ, et al. Tissue factor is rapidly elevated in plasma collected from the pericardial cavity during cardiopulmonary bypass. Thromb Haemost 2000;84: 124-8.
31. De Somer F, Van Belleghem Y, Caes F, et al. Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2002;123:951-8.
32. Laffey JG, Boylan JF, Cheng DC. The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. Anesthesiology 2002;97:215-52.
33. Johnell M, Elgue G, Larsson R, et al. Coagulation, fibrinolysis and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface. J Thorac Cardiovasc Surg 2002;124:321-32.
34. Wagner WR, Johnson PC, Thompson KA, Marrone GC. Heparin-coated cardiopulmonary bypass circuits: hemostatic alterations and postoperative blood loss. Ann Thorac Surg 1994; 58:734-40; discussion 41.
35. Ray MJ, Hales M, Marsh N. Epsilon-aminocaproic acid promotes the release of alpha2-antiplasmin during and after cardiopulmonary bypass. Blood Coagul Fibrinolysis 2001;12: 129-35.
36. Kuitunen AH, Heikkila LJ, Salmenpera MT. Cardiopulmonary bypass with heparin-coated circuits and reduced systemic anticoagulation. Ann Thorac Surg 1997;63:438-44.
37. Ovrum E, Holen EA, Tangen G, et al. Completely heparinized cardiopulmonary bypass and reduced systemic heparin: clinical and hemostatic effects. Ann Thorac Surg 1995;60:365-71.
38. Weerwind PW, Lindhout T, Caberg NE, De Jong DS. Thrombin generation during cardiopulmonary bypass: the possible role of retransfusion of blood aspirated from the surgical field. Thromb J 2003;1:3.
39. Mangano DT. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002;347:1309-17.